drugset
drugset / Trial / NCT01259505

Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer

NCT01259505 ↗

Phase 1 Completed 10 enrolled Tokyo Medical University Saint Luca International Hospital · collabTokyo University · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of HLA-A\*2402 restricted epitope peptides CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 emulsified with Montanide ISA 51.

Timeline

Start
2009-12
Primary completion
2012-06
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CDCA1 Peptide 0.5 mg Subcutaneous
Subject CDCA1 Peptide 1 mg Subcutaneous
Subject CDCA1 Peptide 2 mg Subcutaneous
Subject DEPDC1 Unknown 0.5 mg Subcutaneous
Subject DEPDC1 Unknown 1 mg Subcutaneous
Subject DEPDC1 Unknown 2 mg Subcutaneous
Subject KIF20A Peptide 0.5 mg Subcutaneous
Subject KIF20A Peptide 1 mg Subcutaneous
Subject KIF20A Peptide 2 mg Subcutaneous
Subject MPHOSPH1 Unknown 0.5 mg Subcutaneous
Subject MPHOSPH1 Unknown 1 mg Subcutaneous
Subject MPHOSPH1 Unknown 2 mg Subcutaneous
Subject URLC10 Peptide 0.5 mg Subcutaneous
Subject URLC10 Peptide 1 mg Subcutaneous
Subject URLC10 Peptide 2 mg Subcutaneous
Background incomplete Freund's adjuvant Other / unclassified — Subcutaneous

Indications

breast cancer